88
Participants
Start Date
September 24, 2020
Primary Completion Date
November 15, 2024
Study Completion Date
November 15, 2024
PF-07265807
Given 2 weeks on/1 week off
Sasanlimab
Given SC Q3W
Axitinib
Dosed per package label starting with 5 mg PO BID
Duke Eye Center, Durham
Duke University Medical Center, lnvestigational Chemotherapy Service, Durham
Hospital Universitario Fundacion Jimenez Díaz, Madrid
Hospital Universitario HM Sanchinarro, Madrid
Community Health Network, Inc., Indianapolis
Community Health Network, Inc., Indianapolis
Community Health Network Cancer Center North, Indianapolis
Community Health Network, Inc., Indianapolis
Community Health Network, Inc., Indianapolis
Henry Eye Clinic, Fayetteville
Highlands Oncology Group, Fayetteville
Highlands Oncology Group, Rogers
Highlands Oncology Group, Springdale
The University of Texas M. D. Anderson Cancer Center, Houston
Rocky Mountain Lions Eye Institute (RMLEI), Aurora
University of Colorado Hospital - Anschutz Cancer Pavilion (ACP), Aurora
University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP), Aurora
University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP), Aurora
Istituto Nazionale Tumori IRCCS Fondazione Giovanni Pascale, Napoli
UCI Chao Family Comprehensive Cancer Center, Orange
Clinical & Translational Science Institute, San Francisco
UCSF Helen Diller Family Comprehensive Cancer Center - Mission Hall, San Francisco
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Brigham & Women's Hospital, Boston
Dana Farber Cancer Institute, Boston
Dana-Farber Cancer Institute - Chestnut Hill, Newton
Hackensack University Medical Center, Hackensack
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
University Health Network, Toronto
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore, Roma
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore, Roma
National Cancer Center Hospital East, Kashiwa
Hospital Universitari Vall d'Hebron, Barcelona
Lead Sponsor
Pfizer
INDUSTRY